Alfuzosin
- Generic Name
- Alfuzosin
- Brand Names
- Uroxatral, Xatral
- Drug Type
- Small Molecule
- Chemical Formula
- C19H27N5O4
- CAS Number
- 81403-80-7
- Unique Ingredient Identifier
- 90347YTW5F
- Background
Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over 70. Alfuzosin is an alpha-1 adrenergic b...
- Indication
Alfuzosin is used to treat the signs and symptoms of benign prostatic hyperplasia (BPH).
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH)
- Associated Therapies
- -
Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin
- First Posted Date
- 2006-11-20
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 110
- Registration Number
- NCT00401661
- Locations
- 🇹🇭
Sanofi-Aventis, Bangkok, Thailand
Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia
- Conditions
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2009-10-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1177
- Registration Number
- NCT00399464
- Locations
- 🇯🇵
Sanofi-Aventis, Tokyo, Japan
Alfuzosin for Treating Acute Urinary Retention
- First Posted Date
- 2006-06-15
- Last Posted Date
- 2009-09-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 156
- Registration Number
- NCT00336921
- Locations
- 🇨🇳
Sanofi-aventis, Beijing, China
ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH
- Conditions
- First Posted Date
- 2006-02-10
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 800
- Registration Number
- NCT00290030
ALF-ONE : ALFuzosin ONcE Daily
- Conditions
- First Posted Date
- 2006-01-23
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 200
- Registration Number
- NCT00280605
Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
- First Posted Date
- 2005-02-08
- Last Posted Date
- 2020-06-12
- Target Recruit Count
- 272
- Registration Number
- NCT00103402
- Locations
- 🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸Temple University, Philadelphia, Pennsylvania, United States
🇺🇸Northwestern U. Feinberg School of Medicine, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.